BNN Share Price Performance
€2.99
0.77 (34.68%)
44.9% undervalued intrinsic discount
€5.43
Fair Value
Price €2.99
AnalystConsensusTarget €5.43
AnalystHighTarget €6.50
AnalystLowTarget €5.00
Fair Value€5.43
Share Pricen/a
BRAIN Biotech AG Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
BNN Community Narratives
AN
Fair Value
·Fair Value €5.43 44.9% undervalued intrinsic discount
Biological Solutions And Gene Editing Will Reshape Industrial Processes Over The Next Decade
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value €6.5 54.0% undervalued intrinsic discount
Enzyme Shift And BioIncubator Optionality Will Support Stronger Long Term Outcomes
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value €5 40.2% undervalued intrinsic discount
Production Disruptions And Weak Margins Will Eventually Benefit Consolidated Enzyme Platform
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
BRAIN Biotech
40.2% undervalued intrinsic discount
Production Disruptions And Weak Margins Will Eventually Benefit Consolidated Enzyme Platform
View narrativeAN
Published 2 Mar
BRAIN Biotech
44.9% undervalued intrinsic discount
Biological Solutions And Gene Editing Will Reshape Industrial Processes Over The Next Decade
View narrativeAN
Published 6 Feb
BRAIN Biotech
54.0% undervalued intrinsic discount
Enzyme Shift And BioIncubator Optionality Will Support Stronger Long Term Outcomes
View narrativeAN
Published 21 Jan
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Production Disruptions And Weak Margins Will Eventually Benefit Consolidated Enzyme Platform
Fair Value: €5 40.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Biological Solutions And Gene Editing Will Reshape Industrial Processes Over The Next Decade
Fair Value: €5.43 44.9% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Enzyme Shift And BioIncubator Optionality Will Support Stronger Long Term Outcomes
Fair Value: €6.5 54.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BRAIN Biotech AG Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Jan 14, 2027
- -0.64
- 57.34%
- -30.33%
- 0%
About BNN
- Founded
- 1993
- Employees
- 280
- CEO
- WebsiteView website
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.
